Multiple Myeloma in a 27-Year-Old Female Presenting with Recurrent Low Back Pain
Main Article Content
Abstract
Multiple Myeloma or Kahler's disease is a neoplasm characterized by proliferation of plasma cells in bone marrow where the most common clinical manifestations include bone pain secondary to osteolysis, kidney damage and hypercalcemia. The most common risk factors associated with this pathology are advanced age, family history of multiple myeloma, alcoholism, smoking, among others. Diagnosis includes the presence of monoclonal protein or paraprotein in serum and urine by electrophoresis, presence of free chain protein in 24-hour urine and immunofixation in serum. We present a clinical case of a 27-year-old female patient who presented lumbar pain as the initial manifestation and on requesting laboratory tests showed alterations compatible with myeloma. Laboratory studies were requested confirming the diagnosis of Multiple Myeloma kappa stage ISS-III in current treatment with cyclophosphamide, dexamethasone and thalidomide.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Patel VG, Cornell RF. Cardiovascular complications associated with multiple myeloma therapies: Incidence, pathophysiology, and management. CurrOncolRep [Internet]. 2019;21(4):29. Available at:
http://dx.doi.org/10.1007/s11912-019-0784-4
II. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer [Internet]. 2015;136(5):E359-86. Available at: http://dx.doi.org/10.1002/ijc.29210
III. Curado MP, Oliveira MM, Siulva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin America countries: an update. Cancer Med [Internet].2018; 7(5): 2101-8. Available at: http://dx.doi.org/10.1002/cam4.1347
IV. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo ClinProc [Internet]. 2003;78(1):21-33. Available at: http://dx.doi.org/10.4065/78.1.21
V. Heckmann MB, Doroudgar S, Katus HA, Lehmann LH. Cardiovascular adverse events in multiple myeloma patients. J ThoracDis [Internet]. 2018;10(S35):S4296–305. Available at: http://dx.doi.org/10.21037/jtd.2018.09.87
VI. Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, et al. Risk factors for multiple myeloma: A systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk [Internet]. 2015;15(10):563-77.e1-3. Available at:
http://dx.doi.org/10.1016/j.clml.2015.06.003
VII. Heckmann MB, Doroudgar S, Katus HA, Lehmann LH. Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis [Internet]. 2018;10(S35):S4296–305. Available at:
http://dx.doi.org/10.21037/jtd.2018.09.87
VIII. Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, et al. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. Ann Oncol [Internet]. 2012;23(3):722-9. Available at:
http://dx.doi.org/10.1093/annonc/mdr276
IX. Rajkumar SV, Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc [Internet]. 2016;91(1):101-19. Available from:
http://dx.doi.org/10.1016/j.mayocp.2015.11.007
X. Hsu P, Lin T-W, Gau J-P, Yu Y-B, Hsiao L-T, Tzeng C-H, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine (Baltimore) [Internet]. 2015;94(50):e2305. Available from: